Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12457780 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL21704304 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL21748923 | 1.00 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL91645 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL14113760 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL91646 | 0.84 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2SSTR4 | |
| SCHEMBL21651980 | 0.83 | RET (0.32) | — | |
| SCHEMBL23938167 | 0.81 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20731804 | 0.78 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24730072 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| CN-112236423-A | Piperidinyl-3- (aryloxy) propanamides and propionates | 武田药品工业株式会社 | 2021-01-15 | — | — | CN | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | ALDH1A1 1476/4885SMN1; SMN2 933/4885SSTR4 1/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | ALDH1A1 1476/4885SMN1; SMN2 933/4885SSTR4 1/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | ALDH1A1 1476/4885SMN1; SMN2 933/4885SSTR4 1/4885 |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | ALDH1A1 1476/4885SMN1; SMN2 933/4885SSTR4 1/4885 |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | ALDH1A1 1476/4885SMN1; SMN2 933/4885SSTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.